Drugs / HFA-BDP
HFA-BDP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00829257 | Jan 2009 → Jul 2010 | asthma | University of Dundee | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HFA-BDP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00829257 ↗ |
| Known as | HFA-beclomethasone diproprionate | “Patients then received additional HFA-beclomethasone diproprionate (BDP) 200 µg twice daily or FP 250 µg twice daily for 3 weeks in a crossover.” PMID 22568828 ↗ Jan 2013 |
| Known as | Qvar | “HFA-BDP (Qvar) 100ug 2puff b.i.d” NCT00829257 ↗ |
| Route | Inhaled | “Additional inhaled HFA-BDP reduced FE(NO) and Jaw(NO) without adrenal suppression.” PMID 22568828 ↗ Jan 2013 |